3.5M people in England suffer from a long-term inflammatory condition. Such conditions – including Crohn’s Disease, Ulcerative Colitis and Rheumatoid Arthritis – are characterised by periods of relapse and remission.
During remission, anxiety, depression and other factors can severely impact quality of life. At times of relapse, when flare-management can lead to better outcomes (and reduce hospital admission costs) patients may need rapid access to specialist advice.
Ampersand Health is developing the first scientifically validated digital therapeutic for people with long term inflammatory conditions. Patients track their behaviours, feelings and symptoms and get personalised recommendations. Clinical teams can monitor their patients remotely and intervene when required, safely reducing the number of appointments necessary.
The intervention improves outcomes and quality of life for people living with Inflammatory Bowel Disease and Rheumatoid Arthritis and is shown to reduce health resource utilisation and the overall cost of care.
A surveillance study at King’s College Hospital found:
- 85% of patients were happy to replace all or most of their outpatient appointments with the app
- A 47% reduction in overall outpatient appointments
- A 50% reduction in out-of-hours A&E visits by patients using the app
- Business cases developed with NHS Trusts have forecast (gross) savings of £135-435 per patient per year.
The intervention was co-developed with clinicians and patients from King’s College Hospital and Barts Health. It is CE marked, regulated by the MHRA, and has been assessed by NICE and Orcha.